Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rani Therapeutics Holdings (RANI) Other Non-Current Assets (2021 - 2025)

Rani Therapeutics Holdings has reported Other Non-Current Assets over the past 4 years, most recently at $246000.0 for Q4 2025.

  • Quarterly results put Other Non-Current Assets at $246000.0 for Q4 2025, changed 0.0% from a year ago — trailing twelve months through Dec 2025 was $246000.0 (changed 0.0% YoY), and the annual figure for FY2025 was $246000.0, changed 0.0%.
  • Other Non-Current Assets for Q4 2025 was $246000.0 at Rani Therapeutics Holdings, roughly flat from $245000.0 in the prior quarter.
  • Over the last five years, Other Non-Current Assets for RANI hit a ceiling of $3.4 million in Q2 2021 and a floor of $245000.0 in Q3 2025.
  • Median Other Non-Current Assets over the past 4 years was $246000.0 (2023), compared with a mean of $567200.0.
  • Peak annual rise in Other Non-Current Assets hit 19.11% in 2025, while the deepest fall reached 0.41% in 2025.
  • Rani Therapeutics Holdings' Other Non-Current Assets stood at $3.4 million in 2021, then crashed by 92.79% to $246000.0 in 2023, then changed by 0.0% to $246000.0 in 2024, then changed by 0.0% to $246000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $246000.0 (Q4 2025), $245000.0 (Q3 2025), and $293000.0 (Q2 2025) per Business Quant data.